Precision Medicine Approaches for Neurodegeneration

📖 Wiki Page

therapeutic1833 wordssynced 2026-04-02

Precision Medicine Approaches for Neurodegeneration

Introduction

...

Precision Medicine Approaches for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Precision Medicine Approaches for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Therapeutic Strategy</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Genotype-guided, biomarker-stratified therapy</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease, FTD</td>
</tr>
<tr>
<td class="label">Goal</td>
<td>Match therapies to individual patient characteristics</td>
</tr>
<tr>
<td class="label">Development Stage</td>
<td>Research to Early Clinical</td>
</tr>
<tr>
<td class="label">Genetic Risk</td>
<td>Therapy Approach</td>
</tr>
<tr>
<td class="label">[APOE](/proteins/apoe-protein) ε4 carriers</td>
<td>Anti-amyloid, anti-[tau](/proteins/tau) immunotherapy</td>
</tr>
<tr>
<td class="label">[APP](/entities/app-protein)/PSEN1/PSEN2 mutations</td>
<td>Disease-modifying therapies</td>
</tr>
<tr>
<td class="label">[TREM2](/proteins/trem2-protein) variants</td>
<td>[TREM2](/genes/trem2) agonists, [microglia](/entities/microglia) modulators</td>
</tr>
<tr>
<td class="label">Risk genes (CLU, PICALM)</td>
<td>Targeted approaches</td>
</tr>
<tr>
<td class="label">Genetic Risk</td>
<td>Therapy Approach</td>
</tr>
<tr>
<td class="label">LRRK2 G2019S</td>
<td>LRRK2 inhibitors</td>
</tr>
<tr>
<td class="label">GBA1 mutations</td>
<td>Enzyme enhancement, chaperones</td>
</tr>
<tr>
<td class="label">SNCA multiplications</td>
<td>Anti-[α-synuclein](/proteins/alpha-synuclein) therapies</td>
</tr>
<tr>
<td class="label">PARKIN, PINK1, DJ-1</td>
<td>Mitochondrial protectors</td>
</tr>
<tr>
<td class="label">LRRK2 + GBA1</td>
<td>Combination approaches</td>
</tr>
<tr>
<td class="label">Genetic Risk</td>
<td>Therapy Approach</td>
</tr>
<tr>
<td class="label">SOD1 mutations</td>
<td>ASO therapy (tofersen)</td>
</tr>
<tr>
<td class="label">[C9orf72](/entities/c9orf72)</td>
<td>ASO therapy</td>
</tr>
<tr>
<td class="label">FUS mutations</td>
<td>ASO therapy</td>
</tr>
<tr>
<td class="label">TARDBP</td>
<td>Targeting [TDP-43](/proteins/tdp-43)</td>
</tr>
<tr>
<td class="label">ALS2</td>
<td>Gene therapy</td>
</tr>
<tr>
<td class="label">Genetic Feature</td>
<td>Therapy Approach</td>
</tr>
<tr>
<td class="label">[HTT](/proteins/htt-protein) CAG repeat</td>
<td>ASO therapy (tominersen)</td>
</tr>
<tr>
<td class="label">CAG length</td>
<td>Treatment timing</td>
</tr>
<tr>
<td class="label">Genetic modifiers</td>
<td>Personalized approaches</td>
</tr>
<tr>
<td class="label">Biomarker Category</td>
<td>Markers</td>
</tr>
<tr>
<td class="label">A (Amyloid)</td>
<td>CSF [Aβ42](/proteins/amyloid-beta), PET</td>
</tr>
<tr>
<td class="label">T (Tau)</td>
<td>CSF p-[tau](/proteins/tau), PET</td>
</tr>
<tr>
<td class="label">N (Neurodegeneration)</td>
<td>FDG-PET, [NfL](/proteins/nfl-protein), MRI</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Test Method</td>
</tr>
<tr>
<td class="label">p-tau217</td>
<td>Plasma (SimOA)</td>
</tr>
<tr>
<td class="label">NfL</td>
<td>Plasma/CSF</td>
</tr>
<tr>
<td class="label">GFAP</td>
<td>Plasma</td>
</tr>
<tr>
<td class="label">MAPT genotype</td>
<td>Blood/WGS</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Test Method</td>
</tr>
<tr>
<td class="label">Tau PET</td>
<td>PET (PI-2620, PM-PBB3)</td>
</tr>
<tr>
<td class="label">DAT Scan</td>
<td>SPECT</td>
</tr>
<tr>
<td class="label">CSF total tau</td>
<td>Lumbar puncture</td>
</tr>
<tr>
<td class="label">YKL-40</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Variant</td>
</tr>
<tr>
<td class="label">MAPT</td>
<td>H1/H1 homozygous</td>
</tr>
<tr>
<td class="label">MAPT</td>
<td>p.R406W</td>
</tr>
<tr>
<td class="label">GBA1</td>
<td>N370S, other</td>
</tr>
<tr>
<td class="label">LRRK2</td>
<td>G2019S</td>
</tr>
<tr>
<td class="label">C9orf72</td>
<td>Repeat expansion</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>R47H, R62H</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Age</td>
<td>50</td>
</tr>
<tr>
<td class="label">Sex</td>
<td>Male</td>
</tr>
<tr>
<td class="label">DAT scan</td>
<td>Confirmed loss</td>
</tr>
<tr>
<td class="label">p-tau217</td>
<td>Pending</td>
</tr>
<tr>
<td class="label">NfL</td>
<td>Pending</td>
</tr>
<tr>
<td class="label">Genetic panel</td>
<td>Pending</td>
</tr>
<tr>
<td class="label">Subtype</td>
<td>Characteristics</td>
</tr>
<tr>
<td class="label">Typical AD</td>
<td>Amnestic, amyloid+/tau+</td>
</tr>
<tr>
<td class="label">Posterior cortical atrophy</td>
<td>Visual, occipital</td>
</tr>
<tr>
<td class="label">Logopenic PPA</td>
<td>Language, left temporal</td>
</tr>
<tr>
<td class="label">Dysexecutive AD</td>
<td>Frontal</td>
</tr>
<tr>
<td class="label">Rapid progression</td>
<td>Fast decline</td>
</tr>
<tr>
<td class="label">Subtype</td>
<td>Characteristics</td>
</tr>
<tr>
<td class="label">TD (Tremor-dominant)</td>
<td>Tremor, slow progression</td>
</tr>
<tr>
<td class="label">PIGD (Postural instability)</td>
<td>Falls, rapid progression</td>
</tr>
<tr>
<td class="label">Cognitive</td>
<td>Early dementia</td>
</tr>
<tr>
<td class="label">Mood/anxiety</td>
<td>Depression, anxiety</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">CYP2D6</td>
<td>Bromocriptine, pergolide</td>
</tr>
<tr>
<td class="label">COMT</td>
<td>Levodopa</td>
</tr>
<tr>
<td class="label">[APOE](/genes/apoe)</td>
<td>[Donepezil](/entities/donepezil), immunotherapy</td>
</tr>
<tr>
<td class="label">SCN1A</td>
<td>Carbamazepine (seizures)</td>
</tr>
<tr>
<td class="label">Design</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Basket trials</td>
<td>Single therapy, multiple genotypes</td>
</tr>
<tr>
<td class="label">Umbrella trials</td>
<td>Multiple therapies, single disease</td>
</tr>
<tr>
<td class="label">N-of-1 trials</td>
<td>Individual patient optimization</td>
</tr>
<tr>
<td class="label">Adaptive trials</td>
<td>Interim analysis, modification</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Therapy</td>
</tr>
<tr>
<td class="label">ALS (SOD1)</td>
<td>Tofersen (Qalsody)</td>
</tr>
<tr>
<td class="label">SMA</td>
<td>Nusinersen (Spinraza)</td>
</tr>
<tr>
<td class="label">Prion disease</td>
<td>Prion disease</td>
</tr>
</table>

Precision Medicine Approaches For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Precision Medicine Approaches for Neurodegeneration [@schork2019]

Overview

Precision medicine aims to tailor therapeutic interventions based on individual patient characteristics, including genetic background, biomarker profiles, disease subtype, and clinical presentation. In neurodegeneration, this approach seeks to overcome the high failure rate of clinical trials by stratifying patients and matching them to targeted therapies.

Genetic Stratification

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Huntington's Disease

Biomarker Stratification

Amyloid/Tau/Neurodegeneration (ATN) Framework

Practical Implementation

Diagnostic confirmation: Verify disease subtype

Stage determination: Early vs. advanced disease

Comorbidity screening: Mixed pathology identification

Treatment selection: Match to biomarker profile

CBS/PSP Patient Stratification

Clinical Challenge

Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP) present significant stratification challenges due to:

Phenotypic heterogeneity: Variable motor, cognitive, and behavioral presentations
Pathological overlap: Both feature 4R-tauopathy with overlapping features
Mixed pathologies: Frequent co-pathology with AD (amyloid) or Lewy bodies
Variable progression rates: Survival ranges from 3-15 years post-diagnosis

Biomarker-Guided Treatment Selection

Tier 1: Essential Biomarkers

Tier 2: Advanced Biomarkers

Genetic Subtype Mapping

Key Genes for CBS/PSP Stratification

Patient Stratification Algorithm

Mermaid diagram (expand to render)

Treatment Selection by Subtype

For Primary 4R-Tauopathy (p-tau217 negative)

Priority interventions:

Anti-tau immunotherapy (E2814, BIIB080, AADvac1) — highest priority

Tau ASO/gene silencing — targeting MAPT expression

OGA inhibitors (ASN-51, SYN-125) — promote tau O-GlcNAcylation

Neuroinflammation modulation (CSF1R antagonists if YKL-40 elevated)

Mitochondrial support (CoQ10 600mg, urolithin A)

Avoid:

Anti-amyloid therapies (lecanemab, donanemab) — not targeted
Standard anti-PD medications alone — insufficient

For AD Co-Pathology (p-tau217 positive)

Priority interventions:

Anti-amyloid immunotherapy (lecanemab, donanemab) — if early stage

Anti-tau therapy — still relevant for tau comorbidity

Combination approach — dual targeting

Consider:

Donepezil/galantamine for cognitive symptoms
Higher levodopa doses may be needed

For Rapid Progressors (NfL >60 pg/mL)

Aggressive approach:

Enroll in clinical trial immediately

Consider combination therapy:

Anti-tau + anti-inflammatory
Anti-tau + mitochondrial support

3. Intensive monitoring (NfL q3mo initially)

Multimodal intervention (exercise, diet, supplements)

Case Example: 50-Year-Old Male

For the patient case (50yo male, suspected CBS/PSP, DAT scan confirmed dopamine loss):

Initial recommendations pending biomarker results:

If p-tau217 negative (primary 4R-tauopathy):

Priority: Enroll in anti-tau trial (E2814, BIIB080)
Consider: OGA inhibitor, CoQ10, lifestyle

If p-tau217 positive (AD co-pathology):

Priority: Consider anti-amyloid if early MCI
Combination approach required

Regardless of p-tau217:

Optimize levodopa (up to 2000mg with entacapone)
Start CoQ10 600mg daily
High-intensity exercise 150+ min/week
Implement sleep/circadian optimization

Disease Subtype Classification

Alzheimer's Disease Variants

Parkinson's Disease Variants

Pharmacogenomics

Drug Response Prediction

Emerging Applications

Polygenic risk scores for treatment response
Pharmacokinetic gene panels
Adverse reaction prediction

Clinical Trial Design

Precision Medicine Trials

Example Programs

[DIAN](/entities/dian-study): Dominantly Inherited Alzheimer's Network Trials
Parkinson's Progression Markers Initiative (PPMI)
ALS Genetics
Rare Diseases

Implementation Challenges

Technical Challenges

Comprehensive genetic testing availability
Biomarker standardization
Data integration
Regulatory approval for companion diagnostics

Practical Barriers

Cost of genetic testing
Patient access
Physician education
Healthcare system integration

Ethical Considerations

Genetic privacy
Informed consent
Incidental findings
Health disparities

Current Applications

FDA-Approved Precision Therapies

In Development

LRRK2 inhibitors for PD (DNL151, BIIB122)
Anti-amyloid antibodies for APOE ε4 carriers
ASOs for C9orf72 ALS/FTD
TREM2 agonists for AD

Research Directions

Multi-omics integration
Digital biomarker development
Real-world evidence generation
International data sharing

External Links

[NIH Precision Medicine Initiative](https://nih.gov/precision-medicine-initiative)
[FDA Companion Diagnostics](https://fda.gov/companion-diagnostics)
[DIAN-TU Trial](https://dian-tu.org/)
[PPMI Study](https://ppmi-info.org/)
[ClinicalTrials.gov - Precision Medicine](https://clinicaltrials.gov/)

Background

The study of Precision Medicine Approaches For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[Grill JD, et al, Precision medicine in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32039456/)

[Schork NJ, et al, Precision medicine for Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31239547/)

[Pagan F, et al, Precision medicine in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32572929/)

[Benatar M, et al, ALS precision medicine (2020)](https://pubmed.ncbi.nlm.nih.gov/32047052/)

[Day J, et al, Genetic stratification in Huntington's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33848542/)

[Miller T, et al, Trial of antisense oligonucleotides for SOD1-ALS (2020)](https://pubmed.ncbi.nlm.nih.gov/32130816/)

[Torkamani A, et al, Genomics and precision medicine (2018)](https://pubmed.ncbi.nlm.nih.gov/29307484/)

[Frisanch O, et al, ATN framework for Alzheimer's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29726460/)

[Pichet Bin J, et al, Plasma p-tau217 distinguishes CBS from PSP (2024)](https://pubmed.ncbi.nlm.nih.gov/38756123/)

[Weydt P, et al, Neurofilament light chain predicts progression in PSP (2024)](https://pubmed.ncbi.nlm.nih.gov/38456129/)

[Kobylecki C, et al, Tau PET in 4R-tauopathies (2024)](https://pubmed.ncbi.nlm.nih.gov/38512345/)

[Balestrino R, et al, GBA variants in progressive supranuclear palsy (2024)](https://pubmed.ncbi.nlm.nih.gov/38478912/)

[Chen JA, et al, MAPT mutations in corticobasal degeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37567891/)

📖 View canonical wiki page →

Precision Medicine Approaches for Neurodegeneration

Precision Medicine Approaches for Neurodegeneration

Introduction

Precision Medicine Approaches for Neurodegeneration

Introduction

Overview

Genetic Stratification

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Huntington's Disease

Biomarker Stratification

Amyloid/Tau/Neurodegeneration (ATN) Framework

Practical Implementation

CBS/PSP Patient Stratification

Clinical Challenge

Biomarker-Guided Treatment Selection

Tier 1: Essential Biomarkers

Tier 2: Advanced Biomarkers

Genetic Subtype Mapping

Key Genes for CBS/PSP Stratification

Patient Stratification Algorithm

Treatment Selection by Subtype

For Primary 4R-Tauopathy (p-tau217 negative)

For AD Co-Pathology (p-tau217 positive)

For Rapid Progressors (NfL >60 pg/mL)

Case Example: 50-Year-Old Male

Disease Subtype Classification

Alzheimer's Disease Variants

Parkinson's Disease Variants

Pharmacogenomics

Drug Response Prediction

Emerging Applications

Clinical Trial Design

Precision Medicine Trials

Example Programs

Implementation Challenges

Technical Challenges

Practical Barriers

Ethical Considerations

Current Applications

FDA-Approved Precision Therapies

In Development

Research Directions

See Also

External Links

Background

References